Originally published May 19, 2023 1:08 pm PDT
The U.S. Centers for Disease Control and Prevention (CDC) on Monday declared that the monkeypox outbreak “is not over,” according to a press release distributed via the agency’s ‘Health Alert Network.’
A summary of the announcement indicates that the agency “continues to receive reports of cases that reflect ongoing community transmission in the United States and internationally,” despite cases having declined since peaking in August 2022.
“This week, CDC and local partners are investigating a cluster of mpox cases in the Chicago area,” the press release states. “From April 17 to May 5, 2023, a total of 12 confirmed and one probable case of mpox were reported to the Chicago Department of Public Health.”
All of the cases were among “symptomatic men” but none of the patients have been hospitalized.
Significantly, nine (69%) of 13 cases were among men who had already received 2 doses of the monkeypox “JYNNEOS” vaccine doses.
The CDC admits in their release that “vaccine-induced immunity,” which is protection from the virus acquired through vaccination, “is not complete.”
And although the monkeypox vaccine failed to protect nearly 70% of the patients, the health agency, seemingly in contradiction to the numbers, believes that vaccination “continues to be one of the most important prevention measures.”
The agency recommends vaccination also in spite of the fact that the men were infected after being vaccinated, raising questions regarding whether the vaccine itself is responsible for the illnesses.
In fact, the CDC “expects” new cases “among previously vaccinated people to occur,” according to the release.
The health body is predicting new infections in the spring and summer season in 2023, which “could lead to a resurgence of mpox as people gather for festivals and other events.”
Dr. Richard Bartlett, a former adviser to then-Texas Governor Rick Perry, commented on the matter, saying, “Real-world evidence from Chicago looks like the monkeypox vaccine is ineffective.”
The 30-year physician went on to argue that the public health response to COVID serves as a warning for future public health strategies.
He also highlighted the ethical concerns in offering treatments solely based on product availability or profitability.
“Just because you have a product on the shelf or can make a profit is not an ethical or appropriate medical indication for a treatment to be offered,” he said. “The COVID public health response fiasco appears to be the template for future public health strategies. Tragic.”
Per the release, the purpose of the new announcement is to “inform clinicians and public health agencies about the potential for new clusters or outbreaks of mpox cases and to provide resources on clinical evaluation, treatment, vaccination, and testing.”
However, the CDC’s announcement failed to inform those clinicians and public health agencies about side effects and other concerns related to the Jynneos vaccine, manufactured by Bavarian Nordic, which include the following facts:
- The FDA package insert for Bavarian Nordic’s monkeypox vaccine states that heart problems of “special interest” occur in 1 in 75 vaccine recipients who have not already been vaccinated against smallpox, but also in 1 in 48 vaccine recipients who have already been vaccinated against smallpox. The insert indicates Bavarian Nordic added ‘tromethamine,’ a drug given to treat heart attacks, to the vaccine.
- The CDC has reported how one in four women (25%) who became pregnant after being injected with Bavarian Nordic’s monkeypox vaccine suffered a “spontaneous abortion.”
- The monkeypox vaccine insert also says the vaccine “has not been evaluated” for “[i]mpairment of male fertility.”
- It is not known whether Bavarian Nordic’s monkeypox vaccine is excreted in human breastmilk: “Data are not available to assess the effects of JYNNEOS in the breastfed infant or on milk production/excretion,” the FDA insert reads.
- The insert also warns that the monkeypox vaccine “has not been evaluated for carcinogenic or mutagenic potential,” meaning it is unknown whether the vaccine causes cancer or genetic mutations in humans.
- MIT has reported that Bavarian Nordic’s vice president of clinical strategy, Heinz Weidenthaler, admitted the effectiveness of the company’s monkeypox vaccine has not yet been tested: “[W]e’ve simply had no opportunity to test this in humans,” said Weidenthaler.
- There are no long-term studies evaluating how the monkeypox vaccine will interact with the COVID-19 vaccine, itself already linked to heart disease (here, here, here, here).
- The World Health Organization (WHO) has admitted that the monkeypox vaccine is “not 100% effective” against the virus.
The CDC’s new announcement said that the new cases occurred in 9 (69%) non-Hispanic White men, 2 (15%) non-Hispanic Black men, and 2 (15%) Asian men, the release notes, and the median age was 34 years (range 24–46 years).
Travel history of the infected, which was available for nine cases, indicated four of the men had recently traveled to or from major U.S. cities including New York City, New Orleans, and Mexico.
This raises more concerns about the virus spreading throughout the country.